J Gynecol Oncol.  2015 Jul;26(3):185-192. 10.3802/jgo.2015.26.3.185.

Platinum sensitivity and non-cross-resistance of cisplatin analogue with cisplatin in recurrent cervical cancer

• Takekuma M
• Kuji S
• Tanaka A
• Takahashi
• Abe M
• Hirashima

• KMID: 2160804
• DOI: http://doi.org/10.3802/jgo.2015.26.3.185

Abstract

OBJECTIVE
The concept of platinum sensitivity and cross-resistance among platinum agents are widely known in the management of recurrent ovarian cancer. The aim of this study was to evaluate two hypotheses regarding the validity of the concept of platinum sensitivity and non-cross-resistance of cisplatin analogue with cisplatin in recurrent cervical cancer.
METHODS
In this retrospective study, the clinical data of patients with recurrent cervical cancer, who had a history of receiving cisplatin based chemotherapy (including concurrent chemoradiotherapy [CCRT] with cisplatin) and who received second-line chemotherapy at the time of recurrence between April 2004 and July 2012 were reviewed.
RESULTS
In total, 49 patients-34 squamous cell carcinomas (69.4%) and 15 non-squamous cell carcinomas (30.6%)-were enrolled. The median age was 53 years (range, 26 to 79 years). Univariate and multivariate analysis showed that a platinum free interval (PFI) of 12 months has a strong relationship with the response rate to second-line chemotherapy. Upon multivariate analysis of survival after second-line platinum-based chemotherapy, a PFI of 12 months significantly influenced both progression-free survival (hazard ratio [HR], 0.349; 95% confidence interval [CI], 0.140 to 0.871; p=0.024) and overall survival (HR, 0.322; 95% CI, 0.123 to 0.842; p=0.021). In patients with a PFI of less than 6 months, the difference of progression-free survival between patients with re-administration of cisplatin (3.0 months) and administration of cisplatin analogue (7.2 months) as second-line chemotherapy was statistically significant (p=0.049, log-rank test).
CONCLUSION
The concept of platinum sensitivity could be applied to recurrent cervical cancer and there is a possibility of noncross-resistance of cisplatin analogue with cisplatin.

Keyword

Cisplatin; Disease-Free Survival; Neoplasm Recurrence, Local; Platinum; Uterine Cervical Neoplasms

MeSH Terms

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carboplatin/administration & dosage
Carcinoma, Squamous Cell/*drug therapy/mortality
Cisplatin/administration & dosage/*analogs & derivatives
Drug Resistance, Neoplasm
Female
Humans
Kaplan-Meier Estimate
Middle Aged
Neoplasm Recurrence, Local/*drug therapy
Organoplatinum Compounds/administration & dosage
Retreatment
Retrospective Studies
Treatment Outcome
Uterine Cervical Neoplasms/*drug therapy/mortality
Carboplatin
Cisplatin
Organoplatinum Compounds

Figure

• 

  Fig. 1 Kaplan-Meier curves of overall survival (OS): a platinum free interval (PFI) more than 12 mo vs. less than 12 mo. The median OS: 27.0 mo vs. 12.6 mo, respectively (log-rank test).

• 

  Fig. 2 Kaplan-Meier curves of platinum free interval (PFI) of a PFI of less than 6 mo: administration of cisplatin (CDDP) analogue vs. readministration of CDDP. (A) The median progression-free survival (PFS) of a PFI of less than 6 mo: 7.2 mo vs. 3.0 mo, respectively (log-rank test). (B) The median PFS of a PFI of less than 12 mo: 5.1 mo vs. 3.7 mo, respectively (log-rank test).

Reference

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69–90.

2. Cadron I, Van Gorp T, Amant F, Leunen K, Neven P, Vergote I. Chemotherapy for recurrent cervical cancer. Gynecol Oncol. 2007; 107:1 Suppl 1. S113–S118.

3. Thigpen T, Shingleton H, Homesley H, Lagasse L, Blessing J. Cisplatinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Cancer. 1981; 48:899–903.

4. Long HJ 3rd, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005; 23:4626–4633.

5. Omura GA, Blessing JA, Vaccarello L, Berman ML, Clarke-Pearson DL, Mutch DG, et al. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1997; 15:165–171.

6. Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2004; 22:3113–3119.

7. Tewari KS, Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014; 370:734–743.

8. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991; 9:389–393.

9. Kitagawa R, Katsumata N, Shibata T, Kamura T, Kasamatsu T, Nakanishi T, et al. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: The Open-Label Randomized Phase III Trial JCOG0505. J Clin Oncol. 03. 02. 2015; [Epub]. DOI: 10.1200/JCO.2014.58.4391.

10. Moore DH, Tian C, Monk BJ, Long HJ, Omura GA, Bloss JD. Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2010; 116:44–49.

11. Tanioka M, Katsumata N, Yonemori K, Kouno T, Shimizu C, Tamura K, et al. Second platinum therapy in patients with uterine cervical cancer previously treated with platinum chemotherapy. Cancer Chemother Pharmacol. 2011; 68:337–342.

12. Matoda M, Tanigawa T, Omatsu K, Ushioda N, Yamamoto A, Okamoto S, et al. Platinum-free interval in second-line chemotherapy for recurrent cervical cancer. Int J Gynecol Cancer. 2013; 23:1670–1674.